$PSTX Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share. The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $70.0 million. In addition, Poseida has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. All of the shares to be sold in the offering are to be sold by Poseida. The offering is expected to close on or about August 8, 2022, subject to customary closing conditions.